Efficacy, safety, and cost-effectiveness of atorvastatin 40 mg over 80 mg in reducing LDL-C levels to the target level and reducing major adverse cardiovascular events (MACE) in South Asians presenting with acute coronary syndromes: A Randomized Controlled Trial - Trial SLCTR_2023_003
Access comprehensive clinical trial information for SLCTR_2023_003 through Pure Global AI's free database. This Phase 4 trial is sponsored by Medical Unit, Colombo North Teaching Hospital and is currently Recruiting. The study focuses on Acute Coronary Syndrome.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Sri Lanka Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
SLCTR_2023_003
Phase 4
Recruiting
Trial Details
Sri Lanka Clinical Trials Registry • SLCTR_2023_003
Efficacy, safety, and cost-effectiveness of atorvastatin 40 mg over 80 mg in reducing LDL-C levels to the target level and reducing major adverse cardiovascular events (MACE) in South Asians presenting with acute coronary syndromes: A Randomized Controlled Trial
Efficacy, safety and cost-effectiveness of Atorvastatin 40 mg versus 80 mg in South Asians with Acute Coronary Syndrome: A Randomized Controlled Trial
Study Focus
Interventional
Sponsor & Location
Medical Unit, Colombo North Teaching Hospital
Sri Lanka
Timeline & Enrollment
Phase 4
May 24, 2023
N/A
ICD-10 Classifications
Acute myocardial infarction
Acute myocardial infarction, unspecified
Acute subendocardial myocardial infarction
Acute ischaemic heart disease, unspecified
Other acute ischaemic heart diseases
Data Source
Sri Lanka Clinical Trials Registry
SLCTR_2023_003
Non-Device Trial